Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?

Movement DisordersEarly View HOT TOPICS Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe? Tiago A. Mestre MD, PhD, Corresponding Author Tiago A. Mestre MD, PhD [email protected] orcid.org/0000-0002-6973-7479 Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute/University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Correspondence to: Dr. Tiago A. Mestre, Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada; E-mail: [email protected]Search for more papers by this authorMichael G. Schlossmacher MD, FRCPC, Michael G. Schlossmacher MD, FRCPC Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute/University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa Brain and Research Institute, Ottawa, Ontario, CanadaSearch for more papers by this author Tiago A. Mestre MD, PhD, Corresponding Author Tiago A. Mestre MD, PhD [email protected] orcid.org/0000-0002-6973-7479 Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute/University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Correspondence to: Dr. Tiago A. Mestre, Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada; E-mail: [email protected]Search for more papers by this authorMichael G. Schlossmacher MD, FRCPC, Michael G. Schlossmacher MD, FRCPC Parkinson's Disease and Movement Disorders Clinic, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute/University of Ottawa Brain and Research Institute, Ottawa, Ontario, Canada Program in Neuroscience, Ottawa Hospital Research Institute, University of Ottawa Brain and Research Institute, Ottawa, Ontario, CanadaSearch for more papers by this author First published: 21 March 2023 https://doi.org/10.1002/mds.29382 Relevant conflicts of interest/financial disclosures: Nothing to report. Funding agency: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 2014; 13: 1045– 1060. 2Guiney SJ, Adlard PA, Bush AI, Finkelstein DI, Ayton S. Ferroptosis and cell death mechanisms in Parkinson's disease. Neurochem Int 2017; 104: 34– 48. 3Devos D et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014; 21: 195– 210. 4Martin-Bastida A et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. Sci Rep 2017; 7: 1398. 5Devos D et al. Trial of Deferiprone in Parkinson's disease. N Engl J Med 2022; 387: 2045– 2055. 6Carballo-Carbajal I et al. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis. Nat Commun 2019; 10: 973. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation